Artiva Biotherapeutics, Inc.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$83.9M
- Total assets
- $130.9M
- Market cap
- $332.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $89.8M
- Operating income
- -$89.8M
- Income tax
- $0
- Net income
- -$83.9M
- EPS (basic)
- $-3.43
- EPS (diluted)
- $-3.43
Balance sheet
- Total assets
- $130.9M
- Current assets
- $112.7M
- Total liabilities
- $21.0M
- Current liabilities
- $13.1M
- Shareholders’ equity
- $110.0M
Cash flow
- Operating cash flow
- -$76.8M
- Investing cash flow
- $63.4M
- Financing cash flow
- $9.0K
- Net cash flow
- -$13.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $332.8M
- EPS (diluted)
- $-3.43
- Shares outstanding
- 48.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 19, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $83.9M in FY2025.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Artiva Biotherapeutics, Inc..
Write a review
News about Artiva Biotherapeutics, Inc.
News & sentiment via Polygon.io
